Filana Therapeutics, Inc. (FLNA)
0.699
-0.02
(-2.75%)
USD |
NASDAQ |
Sep 15, 16:00
0.699
0.00 (0.00%)
After-Hours: 20:00
Filana Therapeutics Enterprise Value : -47.96M for Sept. 14, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 14, 2026 | -47.96M |
| September 11, 2026 | -45.36M |
| September 10, 2026 | -43.60M |
| September 09, 2026 | -43.60M |
| September 08, 2026 | -44.17M |
| September 04, 2026 | -43.06M |
| September 03, 2026 | -42.67M |
| September 02, 2026 | -41.25M |
| September 01, 2026 | -41.27M |
| August 31, 2026 | -39.30M |
| August 28, 2026 | -37.80M |
| August 27, 2026 | -38.09M |
| August 26, 2026 | -38.03M |
| August 25, 2026 | -36.85M |
| August 24, 2026 | -37.75M |
| August 21, 2026 | -36.26M |
| August 20, 2026 | -37.15M |
| August 19, 2026 | -36.01M |
| August 18, 2026 | -40.80M |
| August 17, 2026 | -39.69M |
| August 14, 2026 | -38.56M |
| August 13, 2026 | -36.99M |
| August 12, 2026 | -37.60M |
| August 11, 2026 | -35.74M |
| August 10, 2026 | -34.50M |
| Date | Value |
|---|---|
| August 07, 2026 | -34.61M |
| August 06, 2026 | -36.35M |
| August 05, 2026 | -36.32M |
| August 04, 2026 | -34.55M |
| August 03, 2026 | -32.92M |
| July 31, 2026 | -33.89M |
| July 30, 2026 | -36.31M |
| July 29, 2026 | -40.67M |
| July 28, 2026 | -39.93M |
| July 27, 2026 | -39.18M |
| July 24, 2026 | -39.64M |
| July 23, 2026 | -37.65M |
| July 22, 2026 | -36.10M |
| July 21, 2026 | -33.89M |
| July 20, 2026 | -33.41M |
| July 17, 2026 | -31.47M |
| July 16, 2026 | -30.51M |
| July 15, 2026 | -29.54M |
| July 14, 2026 | -30.03M |
| July 13, 2026 | -27.13M |
| July 10, 2026 | -25.68M |
| July 09, 2026 | -25.19M |
| July 08, 2026 | -25.68M |
| July 07, 2026 | -19.40M |
| July 06, 2026 | -22.30M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| CorMedix, Inc. | 500.59M |
| Eloxx Pharmaceuticals, Inc. | 3.827M |
| Cannabis Global, Inc. | -- |
| Breakthrough Chemistry, Inc. | 1.506M |
| BioStem Technologies, Inc. | 69.29M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.603M |
| Total Expenses (Quarterly) | 8.603M |
| EPS Diluted (Quarterly) | -0.1781 |
| Earnings Yield | -125.2% |
| Normalized Earnings Yield | -125.21 |